

REMARKS

Reconsideration of the above-identified application as amended is requested.

Applicants have amended the specification to remove the description of Figures 1 and 2 on page 8 of the specification and all further reference thereto. No new matter is incorporated by these amendments because the description of the Figures in the Boss et al. reference was and is incorporated by reference in its entirety. Accordingly, the reference in the Notice to Comply to omitted Figures 1 & 2 is now not appropriate.


Request under 37 CFR 1.821(e)

Request is hereby made pursuant to 37 CFR 1.821(e), to use the CRF submitted in parent application 09/423,410 filed in the USPTO on November 4, 1999, now issued as US Patent No. 6,620,594 on September 16, 2003. A copy of the paper which references such submission and the Notice of Acceptance of the CRF thereof is hereby attached for the convenience of the Examiner. Reference is made to the 09/423,410 application and computer readable form submitted therein in lieu of filing a duplicate computer readable form in the instant application.

In view of the foregoing, Applicant submits the Application is now in condition for allowance and respectfully requests early notice to that effect.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7831

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date:

3/9/04